OPDUALAG (nivolumab and relatlimab-rmbw)

**Product type:** Human Prescription Drug

**Active ingredient:** NIVOLUMAB; RELATLIMAB

**Strength:** 12; 4 mg/mL; mg/mL

**Dosage form:** Injection

**Route:** Intravenous

**Labeler:** E.R. Squibb & Sons, L.L.C.

**Marketing category:** BLA (BLA761234)

**Pharmacologic class:** Lymphocyte Activation Gene-3 Antagonists [MoA], Lymphocyte Activation Gene-3 Blocker [EPC], Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA]